Alimera Sciences (NASDAQ:ALIM) pared an earlier drop to 6% after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel the company to close its acquisition of Alimera.

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

In May, Alimera Sciences reported a whopping 70% year-on-year increase in net revenue to $23 million on the back of a 23% growth in the global end user demand. The biopharmaceuticals sales company ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is ...

While reporting financial results for the third quarter on Friday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) raised ...

An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that can cause permanent vision loss. The UK cost-effectiveness watchdog says there is ev ...

NASDAQ ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta ...

The fall in earnings was mainly due to an increase in personnel costs as the company ramped up its rare disease organization, as well as the acquisition related costs associated with Alimera Sciences.

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- (ANI or the Company) (Nasdaq: ANIP) today announced that following final ...

The global panuveitis treatment market achieved a significant value of USD 3.76 billion in 2022 and is projected to reach ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is highly synergistic to our Rare Disease business. We believe our proven ...